Patent Description:
Gaboxadol (<NUM>,<NUM>,<NUM>,<NUM>-tetrahydroisoxazolo [<NUM>,<NUM>-c]pyridine-<NUM>-ol) (THIP) is described in <CIT> and in <CIT>, <CIT>, <CIT>,<CIT>, and <CIT>. Gaboxadol is a selective GABAA receptor agonist with a preference for δ-subunit containing GABAA receptors. In the early <NUM> gaboxadol was the subject of a series of pilot studies that tested its efficacy as an analgesic and anxiolytic, as well as a treatment for tardive dyskinesia, Huntington's disease, Alzheimer's disease, and spasticity. In the <NUM> gaboxadol moved into latestage development for the treatment of insomnia. The development was discontinued after the compound failed to show significant effects in sleep onset and sleep maintenance in a three-month efficacy study. Additionally, patients with a history of drug abuse who received gaboxadol experienced a steep increase in psychiatric adverse events.

Treatments for developmental disorders such as Autistic Spectrum Disorder, Rett syndrome, Angelman syndrome, and Fragile X syndrome treatments are limited. For example, Angelman syndrome is a neurodevelopmental disorder caused by loss of function of the UBE3A gene encoding a ubiquitin E3 ligase. Motor dysfunction is a characteristic feature of Angelman syndrome, but neither the mechanisms of action nor effective therapeutic strategies have yet been elucidated. Administering low doses of gaboxadol has been shown to improve the abnormal firing properties of a population of Purkinje cells in cerebellar brain slices and reduces cerebellar ataxia in Ube3a-deficient mice in vivo. These results suggest that pharmacologically increasing tonic inhibition may be a useful strategy for alleviating motor dysfunction in Angelman syndrome.

Accordingly, there remains a need for effective treatments of patients with for developmental disorders, such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome.

Described herein is a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof for use in a method of treating Angelman Syndrome, the method comprising orally administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof, wherein improvement is provided in the patient for more than <NUM> hours after administration.

The references to methods of treatment in the subsequent paragraphs of this description are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method of treatment of the human (or animal) body by therapy.

Described herein are methods of treating Angelman Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof. Many pharmaceutical products are administered as a fixed dose, at regular intervals, to achieve therapeutic efficacy. Its duration of action is reflected by its plasma half-life. Gaboxadol is a selective GABAA receptor agonist with a relatively short half-life (t½ = <NUM>). Since efficacy is often dependent on sufficient exposure within the central nervous system administration of CNS drugs with a short half-life may require frequent maintenance dosing. Advantageously disclosed herein are methods of treating Angelman Syndrome by administration of gaboxadol or a pharmaceutically acceptable salt thereof. For example, in embodiments, methods of treating Angelman Syndrome are provided which include orally administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof, wherein the improvement is provided in the patient for more than <NUM> hours after administration to the patient.

Embodiments described herein provide that a patient in need thereof is administered a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof. Gaboxadol or a pharmaceutically acceptable salt thereof may be provided as an acid addition salt, a zwitter ion hydrate, zwitter ion anhydrate, hydrochloride or hydrobromide salt, or in the form of the zwitter ion monohydrate. Acid addition salts, include but are not limited to, maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethane-disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic or theophylline acetic acid addition salts, as well as the <NUM>-halotheophyllines, for example <NUM>-bromo-theophylline. In other suitable embodiments, inorganic acid addition salts, including but not limited to, hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric or nitric acid addition salts may be used.

In embodiments, gaboxadol is provided as gaboxadol monohydrate. One skilled in the art will readily understand that the amounts of active ingredient in a pharmaceutical composition will depend on the form of gaboxadol provided. For example, pharmaceutical compositions including <NUM> gaboxadol correspond to <NUM> gaboxadol monohydrate.

In embodiments, gaboxadol is crystalline, such as the crystalline hydrochloric acid salt, the crystalline hydrobromic acid salt, or the crystalline zwitter ion monohydrate. In embodiments, gaboxadol is provided as a crystalline monohydrate.

Deuteration of pharmaceuticals to improve pharmacokinetics (PK), pharmacodynamics (PD), and toxicity profiles, has been demonstrated previously with some classes of drugs. Accordingly the use of deuterium enriched gaboxadol is contemplated and within the scope of the methods and compositions described herein. Deuterium can be incorporated in any position in replace of hydrogen synthetically, according to the synthetic procedures known in the art. For example, deuterium may be incorporated to various positions having an exchangeable proton, such as the amine N--H, via proton-deuterium equilibrium exchange. Thus, deuterium may be incorporated selectively or non-selectively through methods known in the art to provide deuterium enriched gaboxadol. See <NPL>).

Deuterium enriched gaboxadol may be described by the percentage of incorporation of deuterium at a given position in the molecule in the place of hydrogen. For example, deuterium enrichment of <NUM>% at a given position means that <NUM>% of molecules in a given sample contain deuterium at that specified position. The deuterium enrichment can be determined using conventional analytical methods, such as mass spectrometry and nuclear magnetic resonance spectroscopy. In embodiments deuterium enriched gaboxadol means that the specified position is enriched with deuterium above the naturally occurring distribution (i.e., above about. In embodiments deuterium enrichment is no less than about <NUM>%, no less than about <NUM>%, no less than about <NUM>%, no less than about <NUM>%, no less than about <NUM>%, no less than about <NUM>%, no less than about <NUM>%, no less than about <NUM>%, or no less than about <NUM>% of deuterium at a specified position.

In embodiments methods of treating Angelman Syndrome include administering to a patient in need thereof a pharmaceutical composition including <NUM> gaboxadol or a pharmaceutically acceptable salt thereof.

Pharmaceutical compositions herein may be provided with immediate release, delayed release, extended release, or modified release profiles. In embodiments, pharmaceutical compositions with different drug release profiles may be combined to create a two phase or three-phase release profile. For example, pharmaceutical compositions may be provided with an immediate release and an extended release profile. In embodiments, pharmaceutical compositions may be provided with an extended release and delayed release profile. Such composition may be provided as pulsatile formulations, multilayer tablets, or capsules containing tablets, beads, granules, etc. Compositions may be prepared using a pharmaceutically acceptable "carrier" composed of materials that are considered safe and effective. The "carrier" includes all components present in the pharmaceutical formulation other than the active ingredient or ingredients. The term "carrier" includes, but is not limited to, diluents, binders, lubricants, disintegrants, fillers, and coating compositions.

In embodiments, the pharmaceutical compositions described herein are administered once daily. In embodiments, a pharmaceutical composition described herein is provided to the patient in the evening. In embodiments, the total amount of gaboxadol or a pharmaceutically acceptable salt thereof administered to a subject in a <NUM>-hour period is <NUM>.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides improvement in at least one symptom of Angelman Syndrome. Symptoms may include, but are not limited to, ataxia, gait, speech impairment, vocalization, cognition, motor activity, clinical seizure, hypotonia, hypertonia, feeding difficulty, drooling, mouthing behavior, sleep difficulties, hand flapping, easily provoked laughter and short attention span. In embodiments, provided in accordance with the present disclosure is improvement in cognition. Cognition refers to the mental processes involved in gaining knowledge and comprehension, such as thinking, knowing, remembering, judging, and problem solving. These higher-level functions of the brain encompass language, imagination, perception, and the planning and execution of complex behaviors.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides improvement of at least one symptom for more than <NUM> hours after administration of the pharmaceutical composition to the patient. In embodiments, the improvement of at least one symptom for more than <NUM> hours after administration of the pharmaceutical composition to the patient is provided in accordance with the present disclosure. In embodiments, improvement of at least one symptom for more than, e.g., <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, or <NUM> hours after administration of the pharmaceutical composition to the patient is provided in accordance with the present disclosure. In embodiments, improvement in at least one symptom for at least e.g., <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, or <NUM> hours after administration of the pharmaceutical composition to the patient is provided in accordance with the present disclosure. In embodiments, improvement in at least one symptom for <NUM> hours after administration of the pharmaceutical composition to the patient is provided in accordance with the present disclosure.

In embodiments, provided herein methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides improvement in next day functioning to the patient.

<FIG> shows the arithmetic mean plasma concentration-time profiles of gaboxadol following single oral doses (<NUM>, <NUM>, <NUM>, <NUM>, and <NUM>)(see, Example <NUM>, below) with horizontal lines Δ indicating the change between <NUM> and <NUM> hours. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile, wherein the in vivo plasma profile of the patient <NUM> hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is reduced by more than <NUM>% and the method provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile, wherein the in vivo plasma profile of the patient <NUM> hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is reduced by more than <NUM>% and the method provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile, wherein the in vivo plasma profile of the patient <NUM> hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is reduced by more than <NUM>% and the method provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile, wherein the in vivo plasma profile of the patient <NUM> hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is reduced by more than <NUM>% and the method provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile, wherein the in vivo plasma profile of the patient <NUM> hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is reduced by more than <NUM>% and the method provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile, wherein the in vivo plasma profile of the patient <NUM> hours after administration of the gaboxadol or pharmaceutically acceptable salt thereof is reduced by more than <NUM>% and the method provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration.

In embodiments, provided herein are methods of treating Angelman Syndrome wherein the amount of gaboxadol or pharmaceutically acceptable salt thereof within the patient about <NUM> hours after administration of the pharmaceutical composition is less than about <NUM>% of the administered dose. In embodiments, provided herein are methods wherein the amount of gaboxadol or pharmaceutically acceptable salt thereof within the patient about, e.g., <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, or <NUM> hours after administration of the pharmaceutical composition is less than about <NUM>%.

In embodiments, provided herein are methods of treating Angelman Syndrome wherein the amount of gaboxadol or pharmaceutically acceptable salt thereof within the patient about <NUM> hours after administration of the pharmaceutical composition is less than about <NUM>% of the administered dose. In embodiments, provided herein are methods wherein the amount of gaboxadol or pharmaceutically acceptable salt thereof within the patient about, e.g., <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, or <NUM> hours after administration of the pharmaceutical composition is less than about <NUM>% of the administered dose.

In embodiments, provided herein are methods of treating Angelman Syndrome wherein the amount of gaboxadol or pharmaceutically acceptable salt thereof within the patient about <NUM> hours after administration of the pharmaceutical composition is between about <NUM>% to about <NUM>% of the administered dose. In embodiments, the amount of gaboxadol or pharmaceutically acceptable salt thereof within the patient after about, e.g., <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, <NUM> hours, or <NUM> hours after administration of the pharmaceutical composition is between about <NUM>% to about <NUM>% of the administered dose.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma concentration <NUM> hours after administration which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma concentration <NUM> hours after administration which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma concentration <NUM> hours after administration which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma concentration <NUM> hours after administration which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma concentration <NUM> hours after administration which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma concentration <NUM> hours after administration which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a Cmax less than about <NUM> ng/ml. In embodiments, the composition provides improvement for more than <NUM> hours after administration to the patient.

In embodiments, the composition provides an in vivo plasma profile having a Cmax less than about, e.g., <NUM> ng/ml, <NUM> ng/ml <NUM> ng/ml, or <NUM> ng/ml and wherein the composition provides improvement of next day functioning of the patient. In embodiments, the composition provides an in vivo plasma profile having a Cmax less than about, e.g., <NUM> ng/ml, <NUM> ng/ml <NUM> ng/ml, or <NUM> ng/ml and wherein the composition provides improvement of next day functioning of the patient.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-∞ of less than about <NUM> ng•hr/ml. In embodiments, the composition provides improvement in next day functioning of the patient. In embodiments, the compositions provide an in vivo plasma profile having a AUC<NUM>-∞ of less than about, e.g., <NUM> ng•hr/ml, <NUM> ng•hr/ml, <NUM> ng•hr/ml, or <NUM> ng•hr/ml and wherein the composition provides improvement of next day functioning of the patient. In embodiments, the composition provides improvement in one or more symptom for more than <NUM> hours after administration.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-∞ of less than about, e.g., <NUM> ng•hr/ml, <NUM> ng•hr/ml, <NUM> ng•hr/ml, <NUM> ng•hr/ml, or <NUM> ng•hr/ml. In embodiments, wherein the composition provides an in vivo plasma profile having a AUC<NUM>-∞ of less than about, e.g., <NUM> ng•hr/ml, <NUM> ng•hr/ml, <NUM> ng•hr/ml, <NUM> ng•hr/ml, or <NUM> ng•hr/ml. In embodiments, the composition provides an in vivo plasma profile having a AUC<NUM>-∞ of less than about, e.g., <NUM> ng•hr/ml, <NUM> ng•hr/ml, <NUM> ng•hr/ml, or <NUM> ng•hr/ml. In embodiments, the composition provides improvement of next day functioning of the patient after administration for more than, e.g., <NUM> hours, <NUM> hours, <NUM> hours, or <NUM> hours, after administration of the composition to the patient.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof an amount of gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof an amount of gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof an amount of gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof an amount of gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof an amount of gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof an amount of gaboxadol or a pharmaceutically acceptable salt thereof which provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the Cmax and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration.

In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration. In embodiments, provided herein are methods of treating Angelman Syndrome including administering to a patient in need thereof a pharmaceutical composition including gaboxadol or a pharmaceutically acceptable salt thereof wherein the composition provides an in vivo plasma profile having a AUC<NUM>-<NUM> which is less than <NUM>% of the administered dose and provides improvement in the patient for more than <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM> or <NUM> hours after administration.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosure herein belongs.

The term "about" or "approximately" as used herein means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within <NUM> or more than <NUM> standard deviations, per the practice in the art. Alternatively, "about" can mean a range of up to <NUM>%, up to <NUM>%, up to <NUM>%, and/or up to <NUM>% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within <NUM>-fold, and more preferably within <NUM>-fold, of a value.

"Improvement" refers to the treatment of Angelman Syndrome measured relative to at least one symptom.

"Improvement in next day functioning" or "wherein there is improvement in next day functioning" refers to improvement wherein the beneficial effect of at least one symptom lasts over a period of time, e.g., <NUM> hours, <NUM> hours, <NUM> hours etc..

"PK" refers to the pharmacokinetic profile. Cmax is defined as the highest plasma drug concentration estimated during an experiment (ng/ml). Tmax is defined as the time when Cmax is estimated (min). AUC<NUM>-∞ is the total area under the plasma drug concentration-time curve, from drug administration until the drug is eliminated (ng•hr/ml). The area under the curve is governed by clearance. Clearance is defined as the volume of blood or plasma that is totally cleared of its content of drug per unit time (ml/min).

"Treating" or "treatment" refers to alleviating or delaying the appearance of clinical symptoms of a disease or condition in a subject that may be afflicted with or predisposed to the disease or condition, but does not yet experience or display clinical or subclinical symptoms of the disease or condition. In certain embodiments, "treating" or "treatment" may refer to preventing the appearance of clinical symptoms of a disease or condition in a subject that may be afflicted with or predisposed to the disease or condition, but does not yet experience or display clinical or subclinical symptoms of the disease or condition. "Treating" or "treatment" also refers to inhibiting the disease or condition, e.g., arresting or reducing its development of at least one clinical or subclinical symptom thereof. "Treating" or "treatment" further refers to relieving the disease or condition, e.g., causing regression of the disease or condition or at least one of its clinical or subclinical symptoms. The benefit to a subject to be treated may be statistically significant, mathematically significant, or at least perceptible to the subject and/or the physician. Nonetheless, prophylactic (preventive) and therapeutic (curative) treatment are two separate embodiments of the disclosure herein.

"Pharmaceutically acceptable" refers to molecular entities and compositions that are "generally regarded as safe"-e.g., that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset and the like, when administered to a human. In embodiments, this term refers to molecular entities and compositions approved by a regulatory agency of the federal or a state government, as the GRAS list under section <NUM>(s) and <NUM> of the Federal Food, Drug and Cosmetic Act, that is subject to premarket review and approval by the FDA or similar lists, the U. Pharmacopeia or another generally recognized pharmacopeia for use in animals, and more particularly in humans.

"Effective amount" or "therapeutically effective amount" means a dosage sufficient to alleviate one or more symptoms of a disorder, disease, or condition being treated, or to otherwise provide a desired pharmacological and/or physiologic effect.

"Patient in need thereof" includes individuals that have been diagnosed with Angelman Syndrome. The methods may be provided to any individual including, e.g., wherein the patient is a neonate, infant, a pediatric patient (<NUM> months to <NUM> years), an adolescent patient (age <NUM>-<NUM> years) or an adult (over <NUM> years).

The Examples provided herein are included solely for augmenting the disclosure herein and should not be considered to be limiting in any respect.

The following Example provides the plasma concentration profiles and dose proportionality of gaboxadol monohydrate following single oral doses ranging from <NUM> to <NUM>. The absolute bioavailability of gaboxadol monohydrate capsules ranging from <NUM> to <NUM> is also assessed.

This study was composed of separate groups of <NUM> healthy adult subjects (at least <NUM> of each gender) who participated in a <NUM>-period, double-blind, randomized, crossover study designed to access the dose proportionality and absolute bioavailability of <NUM> single oral doses of gaboxadol across the dose range of <NUM> to <NUM>. The order in which the subjects received the <NUM> single oral doses of gaboxadol (<NUM>; <NUM>; <NUM>; <NUM>; and <NUM>) was randomized within Treatment Periods <NUM> through <NUM>. Each subject was expected to complete all <NUM> treatment periods and there was a washout of at least <NUM> days between each treatment period.

Each oral dosing within Treatment Periods consisted of <NUM> capsules of test drug taken simultaneously at each scheduled dosing. The treatment designations for the orally administered study drugs were as follows: Treatment A - one <NUM> gaboxadol capsule and <NUM> matching placebo capsule; Treatment B - one <NUM> gaboxadol capsule and <NUM> matching placebo capsule; Treatment C - one <NUM> gaboxadol capsule and <NUM> matching placebo capsule; Treatment D - one <NUM> gaboxadol capsule and <NUM> matching placebo capsule; and Treatment E - <NUM> gaboxadol (two <NUM> gaboxadol capsules). Subjects received their study drug after an overnight fast with <NUM> of water in the morning about <NUM>:<NUM> AM. Water was permitted ad libitum except within <NUM> hour prior to and after study drug administration. No food was allowed for <NUM> hours post dose.

For each subject in each treatment, plasma and urine samples were collected over <NUM> hours post-dosing for the determination of pharmacokinetic parameters (e.g., AUC, Cmax, Tmax, apparent t1/<NUM>, cumulative urinary excretion, renal clearance, clearance, and steady-state volume of distribution, as appropriate). AUC and Cmax for gaboxadol were potency adjusted to facilitate comparison of pharmacokinetic data across studies. Table <NUM> provides the individual potency-adjusted pharmacokinetic parameters of gaboxadol following single oral doses (<NUM>, <NUM>, <NUM>, <NUM>, and <NUM>).

<FIG> shows the arithmetic mean plasma concentration-time profiles of gaboxadol following single oral doses (<NUM>, <NUM>, <NUM>, <NUM>, and <NUM>). The bioavailability of gaboxadol is approximately <NUM>%. Plasma AUC<NUM>-∞ and Cmax of gaboxadol show dose proportional increases and appear to be linear over the entire dose range examined, from of <NUM> to <NUM>. The time to peak plasma concentrations (Tmax <NUM>-<NUM>) and the half-life (t½ of <NUM>) for gaboxadol appear to be independent of dose across the gaboxadol dose range of <NUM> to <NUM>. The excretion of gaboxadol is mainly via urine, where <NUM>% of the dose is recovered; <NUM>% is recovered within <NUM> hours after administration.

This study was a double blind, double-dummy, randomized, active- and placebo-controlled, single dose, <NUM>-period crossover study, followed by an open-label, single-dose, single period study in healthy elderly male and female subjects. Subjects were randomized to each of <NUM> treatments (Treatments A, B, and C) to be administered in a crossover manner over the first <NUM> treatment periods. For Treatment A, subjects received a single dose of gaboxadol <NUM>; for Treatment B, subjects received a single dose of flurazepam <NUM>; and for Treatment C, subjects received a single dose of placebo. Doses were administered orally at bedtime on Day <NUM>. Subjects were domiciled from early in the evening of dosing until ~<NUM> hours post-dose (morning of Day <NUM>) during each treatment period. The subjects who participated in treatment periods <NUM>-<NUM> participated in a fourth treatment period. In this period, a single dose of gaboxadol <NUM> (Treatment D) was administered orally in an open-label manner on the morning of Day <NUM> for PK of gaboxadol. There was at least a <NUM>-day washout between the doses of consecutive treatment periods. Study participants included healthy, elderly male and female subjects between <NUM> and <NUM> years of age, with a Mini Mental Status <NUM>, weighing at least <NUM>. All subjects received <NUM> gaboxadol monohydrate capsules and <NUM> flurazepam (provided as <NUM> x <NUM> capsules), matching placebo was provided for both gaboxadol and flurazepam.

The primary endpoints evaluated included pharmacodynamics (measurement of psychomotor performance, memory, attention and daytime sleepiness the following pm dosing), gaboxadol pharmacokinetics, and safety. Gaboxadol (single dose <NUM>) did not show residual effect <NUM> hours post-dose on the primary endpoints Choice Reaction Time and Critical Flicker Fusion, whereas the active reference Flurazepam (<NUM> single dose) showed significant effect on the same tests. In addition, gaboxadol did not show any signs of residual effects on other measurements applied in the study (Multiple Sleep Latency Test (MSLT); Digit symbol substitution test (DSST), Tracking, Memory tests, Body Sway, and Leeds Sleep Evaluation Questionnaire).

This study was a double blind, randomized, placebo and active controlled <NUM> way cross over study to investigate the effect of evening and middle of the night dosing of gaboxadol on driving performance. The study participants included healthy, male and female subjects between <NUM> and <NUM> years of age, with a valid driver's license for at least <NUM> years.

The effects of gaboxadol on driving performance were investigated using real driving on the road setting. Subjects received <NUM> gaboxadol either in the evening prior to going to bed or at <NUM> am in the middle of the night following a wake-up call. Following a cognitive and psychomotor test battery, the driving test started at <NUM> am and lasted for one hour. Gaboxadol <NUM> had a clinically relevant impairing effect on driving following middle-of-the-night administration.

Following the evening dose, a statistically significant effect of gaboxadol <NUM> was observed on driving. However, this effect was less than the effect observed at a <NUM>% blood alcohol concentration, the concentration limit at which driving is prohibited in most European countries. There was generally a numerically greater effect following zopiclone (<NUM>) and zolpidem (<NUM>) administered in the evening and in the middle of the night, respectively. Both the evening and the middle-of-the-night dose of gaboxadol were well tolerated with the most frequent adverse events being dizziness, nausea and somnolence for the middle-of-the-night treatment and headache and somnolence for the evening treatment.

Subjects on the active reference zopiclone had a numerically greater effect in the same test. There was no effect on memory test, body sway, DSST or critical tracking, whereas zopiclone had effect on several of these tests.

This study was a <NUM>-night, parallel-group, randomized, double-blind (with in- house blinding), placebo-controlled, fixed-dose study to assess the effects of gaboxadol on daytime performance in healthy adults subjected to a <NUM>-hour sleep restriction. The study included a <NUM>- night single-blind placebo run-in period, a <NUM>-night double-blind treatment period during which sleep was restricted to <NUM> hours and a <NUM>-night single-blind placebo run-out period. The study included healthy male and female volunteers <NUM> to <<NUM> years of age.

The primary endpoints included observations based on the Multiple Sleep Latency Test (MSLT) and Slow Wave Sleep (SWS) assessment. The primary objective was to evaluate the efficacy of gaboxadol (<NUM>) compared to placebo in reducing daytime sleep propensity as measured by MSLT. The gaboxadol subjects had significantly less daytime sleepiness during the Sleep Restriction period than did placebo subjects (p=<NUM>, <NUM> sided). The MSLT was on average <NUM> minutes longer for subjects treated with gaboxadol (<NUM>) than for those with placebo on the last two Sleep Restriction days.

In addition, a secondary objective was to evaluate the efficacy of gaboxadol compared to placebo in increasing the amount of slow wave sleep (SWS) during the last <NUM> nights of sleep restriction. Subjects receiving gaboxadol experienced significantly more SWS during the Sleep Restriction period than did placebo subjects (p<<NUM>, <NUM> sided). Moreover, subjects treated with gaboxadol on average had <NUM> minutes of SWS longer than those treated with placebo on the last two Sleep Restriction nights.

Finally, this study examined the efficacy of gaboxadol compared to placebo during the last <NUM> nights/days of sleep restriction in: (<NUM>) improving memory and attention as assessed by a neurobehavioral battery; (<NUM>) reducing subjective sleepiness as measured by the Karolinska Sleepiness Score (KSS); (<NUM>) altering sleep parameters (e.g., total sleep time, latency to onset of Slow Wave Sleep (SWS), slow wave activity (SWA); and (<NUM>) reducing biological stress typified by increased heart rate variability, and decreased cortisol levels and decreased catecholamine levels, as well as decreased body temperature.

There was a trend towards less subjective daytime sleepiness for the gaboxadol subjects during the Sleep Restriction period as compared with placebo subjects. The Karolinska Sleepiness Score (KSS) was on average <NUM> less for subjects treated with gaboxadol than for those treated with placebo on the last two Sleep Restriction days (p=<NUM>, <NUM> sided) as evaluated by a Longitudinal data analysis (LDA) model with adjustment for baseline KSS, gender, and age. A supportive analysis using covariance (ANCOVA) also supports this finding. The effect sizes computed for the neurocognitive battery showed that there was no strong evidence that gaboxadol improves daytime performance. There were no differences between gaboxadol and placebo with respect to biophysiological measures of stress (heart rate variability, cortisol levels, catecholamine levels, body temperature).

Compared with placebo, gaboxadol has a protective effect on reducing daytime sleepiness as measured by the MSLT on the last <NUM> days of <NUM>-nights of sleep restriction. Compared with placebo, gaboxadol increases the amount of slow wave sleep (SWS) during the last <NUM> nights of <NUM>-nights of sleep restriction.

This study is designed to determine whether gaboxadol will lead to an improvement in one or more symptoms of Angelman syndrome. Participants are randomized into <NUM> separate treatment groups (A-F). Inclusion criteria for randomization will require that each participant has been previously diagnosed with Angelman syndrome by clinical evaluation or that the participant is diagnosed with one or more of the major and minor criteria for Angelman syndrome.

After randomization the participants are placed into <NUM> separate treatment groups (A-F) and a placebo group. Treatment group A receives <NUM> gaboxadol in the evening. Treatment group B receives <NUM> gaboxadol in the evening. Treatment group C receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group D receives <NUM> gaboxadol in the evening. Treatment group E receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group F receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning.

Participants are assessed throughout the treatment period to determine whether gaboxadol administration leads to an improvement in one or more symptoms of Angelman syndrome. Several behavioral domains; communication, attention, maladaptive behaviors, and hyper-excitability are assessed. To quantify the communication behavior, participants engage in an unstructured play session to elicit speech and non-verbal communication attempts. Speech attempts by the child are transcribed phonetically and categorized into five different types of vocalizations using the <NPL>) which categorizes non-speech and pre-speech sounds (protophones), as well as vowels, consonants and syllables.

Gait abnormalities occur in most cases of Angelman syndrome. Thus, five primary spatiotemporal parameters are analyzed: cadence, gait velocity, stride width, step length and percent stance. For each parameter, a principal component analysis is used to establish a gait index for assessment of the subjects.

In addition, primary outcome measures that may be assessed include changes in raw or standard scores between baseline and after trial completion of:.

Secondary outcome measures may include normalization of the electroencephalogram (EEG) signature when comparing post gaboxadol administration results to baseline results.

This study is designed to determine whether gaboxadol leads to an improvement in one or more symptoms of Angelman syndrome (AS). Angelman syndrome manifests as several distinct characteristics that range in severity and include developmental delay, movement and/or balance disorder, and tremulous movement of limbs. Perhaps the most unique behavioral characteristic is the combination of a happy demeanor, smiling and frequent of bouts of laughter. Moreover, these individuals possess an easily excitable personality exhibited by hand-flapping or waving movements. Finally, these individuals suffer from severe disruptions in sleep, impairments in speech, and frequent seizures with characteristic abnormal electroencephalogram (EEG) patterns. All main domains of symptoms of AS (sleep, gross and fine motor function, behavior and communication) will be investigated, using appropriate questionnaires, diaries or actimetric data. Main focus may include motor ability and sleep. Well-established scales may be used, complemented by more innovative outcome measures for sleep and motor function. A potential confounding factor for behavior in AS is the co-existence of autism (<NPL>). At Screening, subjects may be assessed for this co-morbidity, using the Autism Diagnostic Observation Schedule (ADOS), and potentially excluded.

The primary objective of this study may be to evaluate the safety and tolerability from Baseline to Week <NUM> and Week <NUM> of gaboxadol in adult subjects with AS across different dose levels and in two dosing schedules. The following dosing schedules may be tested against placebo: (<NUM>) Once daily (o. ): An evening dose, titrated to the target dose of <NUM> unless not tolerated; and (<NUM>) Twice daily (b. ): Evening and morning doses titrated to the target doses of <NUM> evening dose and <NUM> morning dose unless not tolerated.

The Safety endpoints that relate to this study may include: (<NUM>) Frequency and severity of adverse events (AEs) and serious adverse events; (<NUM>) Vital signs (weight, blood pressure, temperature); (<NUM>) Laboratory parameters (electrolytes, lipids, glucose, liver and pancreas function tests, hematology, creatinine); (<NUM>) Suicidality assessed by ABC-Irritability Subscale; (<NUM>) EEG (change in background frequency, intensity of epileptiform discharges); and/or (<NUM>) Caregivers may maintain an electronic seizure diary (on same device as sleep log).

The secondary objective of this study may include the identification of a set of parameters that may best characterize the efficacy of gaboxadol in adult AS subjects for subsequent efficacy trials. These tests may be administered at four full day site visits (Screening, Baseline, Interim and End of Treatment) by an appropriately trained professional to provide the test to an adult AS patient. Assessments may be based on direct observation and input from caregivers. The efficacy assessments that may be explored include Gross Motor Ability/Function and Fine Motor Ability/Function. Evaluation of Gross Motor Ability/Function may include analysis of spatiotemporal and functional gait measurements (Zeno Walkway and PKMAS software analysis, provided by ProtoKintetics) and Modified Performance Oriented Mobility Assessment-Gait (MPOMA-G) scale assessed while subject is walking on Zeno Walkway. Evaluation of Fine Motor Ability/Function may include analysis of Pediatric Evaluation of Disability Inventory (PEDI-CAT); ADL (to document fine motor function) and mobility domains in the content-balanced (more extensive) version.

Evaluation of sleep may include analysis by actigraphy to measure: (<NUM>) Sleep Onset Latency (SOL); (<NUM>) Total Sleep Time (TST); (<NUM>) Wake After Sleep Onset (WASO) = total # of wake epochs after sleep onset; (<NUM>) Nocturnal Awakenings (NA); and/or (<NUM>) Sleep Efficiency = total sleep time (TST) of time in bed (TIB). Additional evaluation of sleep may include analysis of parent/caregiver logs of sleep patterns that may include: (<NUM>) bed time; (<NUM>) time of sleep onset; (<NUM>) number and duration of awakenings; (<NUM>) number of disruptive behavior; (<NUM>) time of last awakening; and (<NUM>) daytime sleepiness. This study may include three treatment groups. For example, a total of approximately <NUM> subjects may be enrolled and at the completion of the study, there may be approximately <NUM> subjects in each of the three treatment groups: <NUM>) single evening dose <NUM>) morning and evening dose and <NUM>) placebo.

All subjects may receive a morning dose (either active or placebo) and an evening dose (either active or placebo) during the entire duration of treatment. For example, as illustrated in <FIG>, two dosing schedules of gaboxadol may be tested: a single evening dose (o. ; Schedule A) and a morning plus evening dose (b. d; Schedule B) designed to provide a more sustained exposure. Schedule C is morning and evening placebo. All subjects may be up-titrated to the target dose unless this target dose is not tolerated (titration conventions described below). All subjects may receive treatment for a maximum of <NUM> weeks at their optimal tolerated dose.

Doses may be progressively increased in <NUM> increments (active or placebo) to a target dose of <NUM> capsules evening dose in schedule A and B, and <NUM> capsules morning dose in schedule B. Each dose escalation may be performed after adequate tolerability has been assessed by caregiver and investigator. For example, treatment initiation at Day <NUM> with <NUM> capsule (active (Act) or placebo (Plc)) in the evening. Then target up-titration may begin at Day <NUM> (window + <NUM> days): If no adverse event (AE) related to the study drug is observed by caregiver and/or the investigator, another capsule (active or placebo) is added in the evening. Again at Day <NUM> (window + <NUM> days), Day <NUM> (window + <NUM> days and Day <NUM> (window + <NUM> days) if no AE related to the study drug is observed by caregiver and/or the investigator, another capsule (active or placebo) may be added in the morning. Table II below provides a graphic illustration of the titration schedule.

Slowed up-titration or delayed up-titration will be acceptable if tolerability does not allow immediate further dose-escalation at any of the above detailed days (<NUM>, <NUM>, <NUM>, <NUM>). Down-titration in the case tolerability is not acceptable (e.g., somnolence, dizziness, change in behavior) after a previous up-titration step or during the course of the <NUM> week treatment, dose can be reduced to the previous level or even further. However, once a tolerable dose has been reached, it shall remain constant for the duration of the treatment period. Once a target dose is achieved the treatment may continue. For example, at Day <NUM>: Earliest day the target dose can be reached (<NUM> capsules in the morning and <NUM> in the evening) the subject may be kept stable until End of Treatment visit (week <NUM>) unless intolerability requires down-titration.

All subjects will be screened for participation in the study up to <NUM> days prior to the first dose administration. Inclusion criteria may include one or more of the following: (<NUM>) Age ≥ <NUM> years, ≤ <NUM> years; (<NUM>) Must possess a clinical diagnosis of AS according to the <NUM> consensus criteria with developmental delay, movement or balance disorder, and speech disorder; (<NUM>) Must possess a previous or current molecular confirmation of AS; (<NUM>) Subjects must be receiving a stable dose of concomitant medications, including anti-epileptic medication, supplements, and special diets, for at least <NUM> weeks prior to Baseline, and be able to maintain these throughout the duration of the study.

Exclusion Criteria may include one or more of the following: (<NUM>) Non-ambulatory subjects (e.g. requiring a wheelchair) not able to perform the tests for Assessment of Motor Ability/Function (as described above); (<NUM>) Poorly controlled seizures defined as > <NUM> absence-type seizure per week and/or > <NUM> major seizure episodes per month; (<NUM>) Concomitant cardiovascular, respiratory diseases; Concomitant liver disease with alanine aminotransferase or aspartate aminotransferase ><NUM> × upper limit of normal (ULN); (<NUM>) Concomitant renal disease with creatinine above ULN (<NUM>) Concomitant hematologic disease with absolute neutrophil count ><NUM> x <NUM><NUM>/L or platelets <<NUM> ×<NUM><NUM>/L or hemoglobin <<NUM>/L; (<NUM>) Other genetic disorders; (<NUM>) Concomitant use of minocycline, levodopa, sleep medication and any other use of any investigational agent, device, and/or investigational procedure <NUM> weeks prior to Baseline and during the study; (<NUM>) At risk of suicide based on ABC- Irritability Subscale.

Descriptive statistics may be used to summarize all primary and secondary endpoints as well as baseline variables, by treatment group. For continuous variables, n, number of missing values, mean, standard deviation, median, minimum, and maximum will be provided. For categorical variables, frequency and percentage will be presented for each category. Confidence intervals (CI) will be provided where meaningful. All CIs will be two-sided <NUM>% confidence intervals.

This study is designed to determine whether lower doses of gaboxadol lead to an improvement in younger patients or patients with less severe clinically evaluated symptoms. For example, adolescent patients (age <NUM>-<NUM> years) may have the similar clinical presentation and baseline disease characteristics as the adult population but the reduction in ambulation may be less severe. In these patients it is anticipated that the target benefit of gaboxadol will also include the reduction in ataxia and the improvement in ambulatory function.

In pediatric patients (<NUM> months to <NUM> years) the diagnosis of Angelman Syndrome is usually made around <NUM> year of age based on important delay in the development status and eventually persistent seizures. As the child grows older, additional neurologic deficit will contribute to the disease presentation leading to ataxia and walking disability. For these prospective participants, the inclusion criteria for randomization and assessment procedures is similar to that previously described.

After randomization the participants are placed into <NUM> separate treatment groups (A-F) and a placebo group. Treatment group A receives <NUM> gaboxadol in the evening. Treatment group B receives <NUM> gaboxadol in the evening. Treatment group C receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group D receives <NUM> gaboxadol in the evening. Treatment group E receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group F receives <NUM> gaboxadol in the evening.

This study is designed to determine whether gaboxadol leads to an improvement in one or more symptoms of Fragile X syndrome. Participants are randomized into <NUM> separate treatment groups (A-F). Inclusion criteria for randomization require patients that have been diagnosed with Fragile X syndrome. For example, patients who are at least moderately ill based on a Clinical Global Impression Severity score of at least <NUM> and have qualifying scores on the ABC-C and IQ test.

After randomization the participants are separated into <NUM> treatment groups (A-F) and a placebo group. Treatment group A receives <NUM> gaboxadol in the evening. Treatment group B receives <NUM> gaboxadol in the evening. Treatment group C receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group D receives <NUM> gaboxadol in the evening. Treatment group E receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group F receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning.

Participants are assessed throughout the treatment period to determine whether administration of gaboxadol leads to an improvement in one or more symptoms of Fragile X syndrome. In particular, patients are assessed using one or more primary and secondary outcome measures. Primary Outcome Measures may include:.

This study is designed to determine whether lower doses of gaboxadol will lead to an improvement in younger patients or patients with less severe clinically evaluated symptoms. For these participants, the inclusion criteria for randomization and assessment procedures will be similar to that previously described.

After randomization the participants are randomized into <NUM> separate treatment groups (A-F) and a placebo group. Treatment group A receives <NUM> gaboxadol in the evening. Treatment group B receives <NUM> gaboxadol in the evening. Treatment group C receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group D receives <NUM> gaboxadol in the evening. Treatment group E will receive <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group F receives <NUM> gaboxadol in the evening.

This protocol is directed to treating symptomatic permutation carriers who have pre-FXTAS or FXTAS symptoms including neuropathy, central pain symptoms, insomnia, and full FXTAS involving tremor and ataxia which is often associated with cognitive decline.

This will be a two-site study. Participants will be individuals with the premutation and FXTAS. FMR1 CGG repeat lengths will be quantified in all subjects using conventional procedures. FXTAS will be diagnosed following published criteria (<NPL>; <NPL>). The study will involve a controlled trial of gaboxadol lasting three months followed by a three month open-label so that those individuals that were treated for the first three months on gaboxadol would continue for a second three months and those individuals on placebo would go on gaboxadol for the second three months. Each site would enroll <NUM> patients per year for a total of <NUM> at each site over a two year period and between the sites there would be <NUM> patients participating.

Identical appearing tablets containing either gaboxadol or placebo will be administered. After randomization the participants are randomized into separate treatment groups and a placebo group. Treatment group A receives <NUM> gaboxadol in the evening. Treatment group B receives <NUM> gaboxadol in the evening. Treatment group C receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group D receives <NUM> gaboxadol in the evening. Treatment group E receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group F receives <NUM> gaboxadol in the evening.

At baseline, and then at three months, and then at six months, the following studies would be done: An assessment of the severity of pain using a pain index and documentation of the type of pain; and a sleep diary will be implemented. Quantitative measures will be implemented using an actometer to observe the severity of sleep disturbances over a one week period of time. Neuropsychological measures would include the Mini-Mental State Examination (MMSE), Behavioral Dyscontrol Scale (BDS-II), Wechsler Memory Scale IV, the California Verbal Learning Test <NUM> (CVLT-<NUM>), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the SCL-<NUM> for a determination of emotional improvements. Any improvements in the MMSE, the BDS-II, and in event related potential (ERP) studies, particularly with the N4 Repetition Paradigm, and in volumetric changes in the hippocampus will be assessed. Motor assessments will be made which documents abnormalities in those with FXTAS compared to other movement disorders. An FXTAS rating scale will be utilized. MRI volumetric studies with the 3Tesla MRI along with DTIs will be conducted. Eye-tracking measures looking at an inhibitory paradigm will be evaluated. The P6 repetition effect over a six month will be evaluated. All of these measures will be at baseline, three months, and six months. Baseline cognitive testing using the Wechsler Scale and WAIS-IV will be carried out also. This could be repeated after one year but typically not sooner. Improvement in neuropathy may be detected and followed through clinical examination using neurodiagnostic studies or electrophysiological studies.

This study is designed to determine whether gaboxadol leads to an improvement in cognitive symptoms, i.e., attentional processes which are fundamental to executive function/dysfunction associated with Fragile X-associated tremor/ataxia syndrome (FXTAS) and involves a placebo-controlled, double-blind, randomized clinical trial and an auditory "oddball" task. Participants will be individuals with FXTAS. FMR1 CGG repeat lengths will be quantified in all subjects using conventional procedures. FXTAS will be diagnosed following published criteria (<NPL>; <NPL>). For the main gaboxadol trial, <NUM> potential participants will be screened for eligibility. Randomization to either placebo or gaboxadol will be blinded to all study personnel, investigators, and participants until the end of the one year trial period. Participants will participate in an auditory "oddball"/event related potentials (ERPs) experiment.

Identical appearing tablets containing either gaboxadol or placebo will be administered. After randomization the participants are randomized into <NUM> separate treatment groups (A-F) and a placebo group. Treatment group A receives <NUM> gaboxadol in the evening. Treatment group B receives <NUM> gaboxadol in the evening. Treatment group C receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group D receives <NUM> gaboxadol in the evening. Treatment group E receives <NUM> gaboxadol in the evening and <NUM> gaboxadol in the morning. Treatment group F receives <NUM> gaboxadol in the evening.

In the auditory "oddball" experiment, patients will be instructed to detect an infrequent "oddball" tone embedded in a train of non-target standard tones. Subjects will press a button to each target detected and also keep a mental count of the number of targets in that experimental block. Prior studies in premutation carriers using the same "oddball" paradigm have demonstrated an altered frontal P300 (P3) ERP component in FXTAS patients, which tracks their executive dysfunction. See, <NPL>); <NPL>). In these studies and others, the earlier abnormalities of prolonged N100 latency and reduced P200 (P2) amplitude were also found in a predominately male FXTAS group but not in female premutation carriers asymptomatic of FXTAS9.

Neuropsychological testing will involve examining each patient's EEG. Accordingly, EEG during a two-stimulus auditory oddball experiment will be recorded in a sound-attenuated, dimly-lit chamber. Lower (<NUM>) and higher (<NUM>) frequency pure tones will be presented at <NUM> dB above individual hearing level in <NUM> blocks, each containing <NUM> tones, with a stimulus onset asynchrony jittered from <NUM>-<NUM> seconds. Prior to each block, subjects will be instructed to respond to the infrequent (probability equaling <NUM>%) "oddball" tones (high or low target tones, counterbalanced across blocks). A dual task will be employed in which subjects are instructed to press a button to each target tone, and to also keep a mental count of the number of targets in each block. The mental count of target tones will be reported immediately following completion after each block. <NUM>-channel EEG will be recorded with a Nicolet-SM-<NUM> amplifier (band-pass = <NUM>-<NUM>, sampled at <NUM>). Data Analysis will involve the |count-hit| discrepancy in each block (i.e., the absolute value of the difference between correct button-presses and mental count to target tones within a block) will be calculated for each participant, as an inverse measure (i.e., a lower value represents better performance) of attention/working memory performance during the oddball task. Event-locked EEG segments contaminated with blinks, eye movements, excessive muscle activity, or amplifier blocking will be rejected using a semi-automated computer algorithm. Artifact-free EEG segments of <NUM> (with a <NUM> pre-stimulus baseline period, and <NUM> post-stimulus onset) will be averaged by experimental condition to obtain the ERPs. Mean amplitude and local peak latency of <NUM> ERP components will be quantified in the following time windows: N100 (N1, <NUM>-<NUM>), P2 (<NUM>-<NUM>), N200 (N2, <NUM>-<NUM>), and P3 (<NUM>-<NUM>). The waveforms to both target and standard tones will be used to measure N1. The P2 will be measured from ERPs to standard tones. The N2 component is defined from the difference wave (ERPs to targets minus standards). The P3 will be measured from both the difference wave and the ERP waveform to targets. ERP measures will be submitted to repeated-measures ANOVAs (SPSS <NUM>, IBM) with the between-subjects factor of treatment, and the within-subjects factors of visit and electrode. Analyses of N1 and P2 will include <NUM> fronto-central electrodes (Fz, Cz, FC1/<NUM>). Five central channels (Cz, FC1/<NUM>, CP1/<NUM>) will be used for the N2 analyses. P3 analyses will be carried out with <NUM> scalp electrodes (all except FP1/<NUM>). The Greenhouse-Geiser correction will be used to adjust for violations of sphericity, where appropriate. To further characterize the modulatory effects of gaboxadol on the P2 component, a habituation analysis will be conducted for P2 amplitude. P2 mean amplitude in response to the first <NUM> standard tones will be compared to the amplitude of response to the last <NUM> standard tones within the first block of each study, with the between-subjects factor of treatment, and the within-subjects factors of visit, trial position, and electrode. Data from a group of <NUM> age-matched normal controls, each of whom will have only underwent one ERP recording, will be used to demonstrate the normal habituation effect. Linear regression will be used to examine the correlations between changes (<NUM>-year follow-up minus baseline) in the |count-hit| discrepancy and in ERP measures for which significant treatment effects are shown. Correlations between local peak amplitudes of P2 (measured after application of a <NUM> low-pass filter) and CGG repeats will be tested.

Claim 1:
A pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof for use in a method of treating Angelman Syndrome, the method comprising orally administering to a patient in need thereof a once daily dose of the composition, the once daily dose comprising <NUM> gaboxadol or pharmaceutically acceptable salt thereof, wherein improvement is provided in the patient for more than <NUM> hours after administration.